Regulation of Calcitonin Gene-Related Peptide Secretion from Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy

Headache

Volumn 44, Issue 1, 2004, Pages 35-43

  Durham, Paul L ^a   Cady, Ryan ^a   Cady, Roger ^b   Blumenfeld, Andrew J ^c  

^a MISSOURI STATE UNIVERSITY   (United States)

^b HEADACHE CARE CENTER   (United States)

^c 225 Temple Hall ^*

Author keywords

Botox; Botulinum toxin type A; CGRP; Migraine; Trigeminal nerve

Indexed keywords

BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; POTASSIUM CHLORIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; IMMUNOHISTOCHEMISTRY; MIGRAINE; NERVE CELL CULTURE; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE FIBER C; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; RAT; TRIGEMINUS GANGLION;

EID: 1642568305     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04007.x     Document Type: Article

References (47)

1. 1 Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002 ; 8: 136 ‐ 142.
2. 2 Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia. 1995 ; 15: 277 ‐ 280.
3. 3 Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001 ; 53: 167 ‐ 178.
4. 4 Edvinsson L. Calcitonin gene‐related peptide (CGRP) and the pathophysiology of headache. CNS Drugs. 2001 ; 15: 745 ‐ 753.
5. 5 Van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 199x ; 21: 649 ‐ 678.
6. 6 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 ; 33: 48 ‐ 53.
7. 7 Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attack therapies. Brain. 1994 ; 117: 427 ‐ 434.
8. 8 Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia. 1994 ; 14: 320 ‐ 327.
9. 9 Fanciullacci M, Alessandri M, Figini M, et al. Increase in plasma calcitonin gene‐related peptide from the extracerebral circulation during nitroglycerine‐induced cluster headache attack. Pain. 1995 ; 60: 119 ‐ 123.
10. 10 Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene‐related peptide seen in the headache phase of migraine. Cephalalgia. 1991 ; 11 (suppl 11): 3 ‐ 4.
11. 11 Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5HT 1 ‐like receptor agonist, GR43175. Cephalalgia. 1989 ; 9 (suppl 9): 23 ‐ 33.
12. 12 Binder WJ, Brin MF, Blitzer A, et al. BTXA for the treatment of migraine headaches: an open label study. Otolaryngol Head Neck Surg. 2000 ; 123: 669 ‐ 676.
13. 13 Mauskop A, Basdeo R. BTXA is an effective prophylactic therapy fpr migraines. Cephalalgia. 2000 ; 20: 442.
14. 14 Silberstein S, Mathew N, et al. BTXA as a migraine preventative treatment. Headache. 2000 ; 40: 445 ‐ 450.
15. 15 Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP‐25. Nature. 1993 ; 365:
16. 16 Physicians' Desk Reference. 57th ed. 2000 ; 552.
17. 17 Pikoff H. Is the muscular model of headache still viable? A review of conflicting data. Headache. 1984 ; 24: 186 ‐ 198.
18. 18 Jensen R. Mechanisms of spontaneous tension‐type headache: an analysis of tenderness, pain thresholds and EMG. Pain. 1995 ; 64: 251.
19. 19 Blersch W, Schulte‐Mattler W, Przywara S, et al. BTXA and the cutaneous nociception in humans: a prospective, double‐blind, placebo controlled, randomized study. J Neurol Sci. 2002 ; 205: 59 ‐ 63.
20. 20 Duggan MJ, Quinn CP, Chaddock JA, et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and erythrina cristagalli lectin. J Biol Chem. 2002 ; 277: 34846 ‐ 34852.
21. 21 Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000 ; 38: 245 ‐ 258.
22. 22 Durham PL, Russo AF. Regulation of calcitonin gene‐related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999 ; 19: 3423 ‐ 3429.
23. 23 Durham PL, Sharma R, Russo AF. Repression of calcitonin gene‐related peptide promoter by 5‐HT 1 receptor activation. J Neurosci. 1997 ; 17: 9545 ‐ 9553.
24. 24 Durham PL, Russo AF. Stimulation of the calcitonin gene‐related peptide enhancer by mitogen‐activated protein kinase and repression by an antimigraine drug in trigeminal ganglia neurons. J Neurosci. In press.
25. 25 Steen KH, Reeh PW, Anton F. Proton selectively induce lasting excitation and sensitization to mechanical stimulation of nociceptors in rat skin, in vitro. J Neurosci. 12: 86 ‐ 95.
26. 26 Strassman AM, Raymond SA, Burstein R. Sensitization off meningeal sensory neurons and the origins of headaches. Nature. 1996 ; 384: 560 ‐ 564.
27. 27 Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992 ; 267: 64 ‐ 69.
28. 28 Lipton RB, Diamond S, Reed ML, et al. Migraine diagnosis and treatment: results of the American Migraine Study II. Headache. 2001 ; 41: 538 ‐ 645.
29. 29 Lassen LH, Hadersley PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2001 ; 22: 54 ‐ 61.
30. 30 Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000 ; 123: 1703 ‐ 1709.
31. 1 Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX ® Migraine Clinical Research Group. Headache. 2000 ; 40: 445 ‐ 450.
32. 2 Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache. 2003 ; 43: 853 ‐ 860.
33. 3 Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache. 2003 ; 43 (suppl 1): S25 ‐ S33.
34. 4 Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. 2002 ; 6: 460 ‐ 469.
35. 5 Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987 ; 2: 237 ‐ 254.
36. 6 Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003 ; 43 (suppl 1): S9 ‐ S15.
37. 7 Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001 ; 248: 3 ‐ 10.
38. 8 Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001 ; 10: 1531 ‐ 1544.
39. 9 Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003 ; 43 (suppl 1): S16 ‐ S24.
40. 10 Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci. 1997 ; 152: 132 ‐ 135.
41. 11 Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000 ; 38: 245 ‐ 258.
42. 12 Durham PL, Cady R, Cady R. Regulation of calcitonin gene‐related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004 ; 44: 34 ‐ 42
43. 13 Durham P, Russo A. New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacol Ther. 2002 ; 94: 77 ‐ 92.
44. 14 Durham PL, Russo AF. Stimulation of the calcitonin gene‐related peptide enhancer by mitogen‐activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. J Neurosci. 2003 ; 23: 807 ‐ 815.
45. 15 Purkiss J, Welch M, Doward S, Foster K. Capsaicin‐stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2000 ; 59: 1403 ‐ 1406.
46. 16 Cui M, Li S, Khanijou S, Aoki K. Subcutaneous BOTOX inhibits formalin‐induced local neurotransmitter release and spinal nociceptive processing. Presented at: the 10th World Congress on Pain ; August 17-22, 2002 ; San Diego, CA, USA.
47. 17 Ishikawa T, Nakanishi O, Funatsu N, Kameyama H. Nerve growth factor inducer, 4‐methyl catechol, potentiates central sensitization associated with acceleration of spinal glutamate release after mustard oil paw injection in rats. Cell Mol Neurobiol. 1999 ; 19: 587 ‐ 596.